ArriVent BioPharma (AVBP) Q4 2024 earnings summary

Executive summary

• Achieved target enrollment in global Phase 3 study of firmonertinib for first-line NSCLC with EGFR exon 20 insertion mutations; top-line data expected in 2025.

• Presented first clinical data showing robust responses and CNS anti-tumor activity for firmonertinib in EGFR PACC mutant NSCLC.

• Expanded ADC pipeline with in-licensing of ARR-217 and selection of ARR-002 for IND-enabling studies.

• Completed IPO in 2024, raising $183.2 million in net proceeds.

Financial highlights

• Cash, cash equivalents, and investments totaled $266.5 million as of December 31, 2024, expected to fund operations into 2026.

• Net cash used in operations was $70.2 million for 2024, up from $55.8 million in 2023.

• Research and development expenses rose to $79.0 million in 2024 from $64.9 million in 2023, mainly due to increased headcount and clinical activity.

• General and administrative expenses increased to $15.3 million in 2024 from $9.7 million in 2023, reflecting public company infrastructure costs.

• Net loss was $80.5 million for 2024, compared to $69.3 million in 2023.

Outlook and guidance

• Top-line pivotal Phase 3 data for firmonertinib in EGFR exon 20 insertion mutant NSCLC expected in 2025; update on timing in Q2 2025.

• Update on development plans for firmonertinib in EGFR PACC mutant NSCLC anticipated in the first half of 2025.

• First IND filing for ADC candidate ARR-217 planned for the first half of 2025.